Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 4/20 | 0.60 |
| ▸ | F10 | P00742 | 3/20 | 0.60 |
| ▸ | PPID | Q08752 | 1/20 | 0.33 |
| ▸ | P2RY12 | Q9H244 | 5/20 | 0.32 |
| ▸ | TGM2 | P21980 | 3/20 | 0.32 |
| ▸ | CCKBR | P32239 | 1/20 | 0.31 |
| ▸ | NPY1R | P25929 | 2/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
| ▸ | KDM1A | O60341 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6543946 | 1.00 | F2 (0.60) | F2F10PPIDP2RY12TGM2 | |
| SCHEMBL6544384 | 0.88 | F2 (0.48) | F2F10P2RY12TGM2CCKBR | |
| SCHEMBL6544377 | 0.88 | F2 (0.48) | F2F10P2RY12TGM2CCKBR | |
| SCHEMBL6604658 | 0.85 | F2 (0.53) | F2F10 | |
| SCHEMBL6604650 | 0.85 | F2 (0.53) | F2F10 | |
| Hydrochloric Acid SCHEMBL6543162 | 0.84 | F2 (0.55) | F2F10 | |
| Hydrochloric Acid SCHEMBL6543158 | 0.84 | F2 (0.55) | F2F10 | |
| SCHEMBL6606793 | 0.83 | F2 (0.45) | F2F10CCKBR | |
| SCHEMBL7137947 | 0.80 | F2 (0.50) | F2F10 | |
| SCHEMBL7137941 | 0.80 | F2 (0.50) | F2F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1268469-B1 | N-(HETEROCYCLYL)BENZENE OR PYRIDINE SULPHONAMIDES AS ANTITHROMBOTIC AGENTS AND ANTICOAGULANTS | SANOFI SYNTHELABO (FR) | 2004-06-16 | — | — | EP | disclosed |
| US-6680329-B2 | N-(heterocyclyl)benzene or pyridinesulphonamides as antithrombotic agents and anticoagulants | SANOFI-SYNTHELABO (FR) | 2004-01-20 | — | — | US | disclosed |
| US-20030207920-A1 | N-(heterocyclyl)benzene or pyridinesulphonamides as antithrombotic agents and anticoagulants | SANOFI-AVENTIS (FR) | 2003-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207920-A1 | N-(heterocyclyl)benzene or pyridinesulphonamides as antithrombotic agents and anticoagulants | PROC, VKORC1, SERPINC1 | F2 7/4885F10 99/4885PPID 535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.